BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Young Innovations, Inc. (YDNT) Announces Record Sales and EPS for the Quarter Ended March 31, 2012


4/24/2012 10:00:17 AM

ST. LOUIS, April 23, 2012 /PRNewswire/ -- Young Innovations, Inc. (NASDAQ: YDNT) today announced sales and earnings per share for the quarter ended March 31, 2012.

Sales for the first quarter of 2012 were $26.8 million, an increase of 2.8% from $26.0 million reported in the first quarter of 2011. Income from operations increased 5.3% to $6.1 million in the first quarter of 2012 from $5.8 million in the first quarter of 2011. Net income increased 5.6% to $4.2 million compared with $4.0 million in the first quarter of 2011. Diluted earnings per share increased 8.0% in the first quarter of 2012 to $0.54 from $0.50 in the prior year quarter.

We are pleased with the Company's sales performance in the quarter. Sales continued to benefit from solid overall demand and recent new product introductions under both our consumable and diagnostic product lines. Favorable product mix and increases in operating efficiencies helped improve our operating income for the quarter. The Company also recognized a gain in the quarter from its private equity investment of approximately $0.04 per share, which was recorded as "other income." In the first quarter of 2011, the Company also recorded a gain of $0.04 per share from the private equity investment.

We remain focused on driving internal growth through enhancing customer relationships, increasing operating efficiencies, and new product development. During the quarter, we continued to focus on the launch of new cup styles under our popular Elite polishing line. We enhanced our e-commerce capabilities to improve our online interactions with customers. We also invested in new capital equipment to increase production capacity. Finally, we ended the quarter with $5.2 million of cash on our balance sheet, up $4.2 million from the end of 2011.

A conference call has been scheduled for Tuesday, April 24, 2012 at 10:00 A.M. Central Time and can be accessed through InterCall at http://tinyurl.com/YI-Quarter12012 or on the Company's website, www.ydnt.com.

Young Innovations develops, manufactures and markets supplies and equipment used by dentists, dental hygienists, dental assistants and consumers. The Company's consumables product offering includes disposable and metal prophy angles, prophy cups and brushes, dental micro-applicators, moisture control products, infection control products, dental handpieces (drills) and related components, endodontic systems, orthodontic toothbrushes, flavored examination gloves, children's toothbrushes, and children's toothpastes. In addition, the Company offers a line of diagnostic products that includes panoramic X-ray machines and related supplies. The Company believes it is a leading U.S. manufacturer or distributor of prophy angles and cups, liquid surface disinfectants, dental micro-applicators and obturation units designed for warm, vertical condensation.

Investors are cautioned that this press release as well as other reports and oral statements by Company officials may contain certain forward-looking statements as defined in the Private Securities Litigation and Reform Act of 1995. Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions and which include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," or similar expressions. These statements are not guaranties of future performance and the Company makes no commitment to update or disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements. Because such statements involve risks and uncertainties, actual actions and strategies and the timing and expected results thereof may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, those disclosed in the Company's Annual Report on Form 10-K and other reports filed with the Securities and Exchange Commission.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES